<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02758652</url>
  </required_header>
  <id_info>
    <org_study_id>R15134</org_study_id>
    <nct_id>NCT02758652</nct_id>
  </id_info>
  <brief_title>Molecular Mechanisms Leading to Chemoresistance in Epithelial Ovarian Cancer</brief_title>
  <acronym>CHEMOVA</acronym>
  <official_title>Molecular Mechanisms Leading to Chemoresistance in Epithelial Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tampere University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Tampere</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helsinki University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tampere University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Epithelial ovarian cancer is the most lethal gynecological malignancy in developed countries
      and the fifth most common cause of cancer-related death in women. Poor prognosis is due to
      challenges in early diagnosis and development of inevitable resistance to chemotherapy in
      majority of patients despite of good initial treatment response. The purpose of this
      prospective study is to analyze variation in microRNA expression in prediction of primary
      treatment response and the role of microRNAs in development of chemoresistance in epithelial
      ovarian cancer.

      • Objectives: To screen microRNAs from prospectively collected plasma, urine and tumor
      samples from patients diagnosed with epithelial ovarian cancer. Samples are analyzed for
      microRNA expression and differential expression is correlated with primary treatment
      response, progression-free survival and overall survival.

      • Methods: Plasma, urine and tumor samples are collected at primary surgery (open surgery or
      diagnostic laparoscopy) or interval debulking surgery, at 1st, 3rd and 6th neoadjuvant or
      adjuvant chemotherapy and at progression for high-throughput screening of microRNA expression
      by array technology.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion criteria:

      patients operated for a suspected ovarian malignancy in the Department of Obstetrics and
      Gynecology in Tampere University Informed consent obtained
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">May 2026</completion_date>
  <primary_completion_date type="Anticipated">April 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>miRNA expression profile as measured by miRNA array</measure>
    <time_frame>5 years</time_frame>
    <description>Expression profile calculated with bioinformatical analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Time from diagnosis to disease relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Over-all survival</measure>
    <time_frame>5 years</time_frame>
    <description>Timo from diagnosis to death</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ovarian Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma, urine and tissue samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Newly diagnosed epithelial ovarian cancer patients operated inTampere University Hospital,
        Finland.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age, informed consent.

        Exclusion Criteria:

          -  Informed consent not provided, age under 18 years.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annika Auranen, adj prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chief of Gynecological Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Annika Auranen, adj prof</last_name>
    <phone>+358331164650</phone>
    <email>annika.auranen@pshp.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kalle Savolainen, MD,PhD</last_name>
    <email>kalle.savolainen@pshp.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annika Auranen, Adj prof</last_name>
      <phone>+358331164650</phone>
      <email>annika.auranen@pshp.fi</email>
    </contact>
    <contact_backup>
      <last_name>Kalle Savolainen, MD,PhD</last_name>
      <email>kalle.savolainen@pshp.fi</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2016</study_first_submitted>
  <study_first_submitted_qc>April 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2016</study_first_posted>
  <last_update_submitted>May 6, 2016</last_update_submitted>
  <last_update_submitted_qc>May 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tampere University Hospital</investigator_affiliation>
    <investigator_full_name>Annika Auranen</investigator_full_name>
    <investigator_title>Chief in gynecological oncology</investigator_title>
  </responsible_party>
  <keyword>chemoresistance</keyword>
  <keyword>miRNA</keyword>
  <keyword>microRNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

